CLINICAL TRIALS PROFILE FOR COLCHICINE; PROBENECID

All Clinical Trials for colchicine; probenecid

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01021020 ↗	Bioequivalence Study of Colchicine Tablets	Completed	Mutual Pharmaceutical Company, Inc.	Phase 1	2007-09-01	This randomized, single dose, three-way crossover study will evaluate the bioequivalence of two formulations of colchicine, the test product (colchicine 0.6mg Mutual) and a marketed combination product (colchicine 0.5 mg with probenecid 500 mg), administered under fasting conditions. It will also determine the bioavailability following a standard high-fat meal and evaluate the safety and tolerability of the test product.
NCT05499312 ↗	An Innovative Chinese Herbal Formula for the Treatment of Gout	Not yet recruiting	Chinese University of Hong Kong	Phase 2	2022-09-01	Gout is a chronic disease of deposition of monosodium urate crystals, which form in the presence of increased urate concentrations. Gout is closely related to hyperuricaemia. Urate deposits in the joint, causing joint swelling, pain, movement disorders, affecting a significant portion of the population worldwide annually. The underlying pathophysiology of gout is multifactorial, complex, and poorly understood. Thus, gout remains one of the major therapeutic challenges. Currently, western medicine treatment of gout flare includes colchicine, NSAIDs and glucocorticoids. These drugs act as analgesics, anti-inflammatory and uric acid lowering drugs. Besides, management of gout and prevention of acute flares of gout make a crucial part in gout management. To obtain uricemia target, urate lowering treatment (ULT) has been widely used in conventional management of gout. Allopurinol, probenecid and febuxostat are some of the examples of ULT. Although researchers have carried out various studies on this disease, there are severe side effects for patients with gout. Therefore, it is necessary to explore new treatments for gout with good efficacy and less side effects. Chinese medicine (CM) is nowadays widely used for managing gout in China and other East Asian countries. Our principal Investigator (Prof. Zhi-xiu Lin), a highly experienced Registered Chinese Medicine Practitioner working at the School of Chinese Medicine, The Chinese University of Hong Kong, has been using a herbal formula (HKIIM-KU formula) to treat patients with gout in Hong Kong for many years. This formula has been observed to be effective in relieving and preventing gout and its related clinical manifestations. Hence, a double-blind, randomized, placebo-controlled, multicenter clinical trial will be employed in this study, and it would be able to provide robust clinical evidence on the efficacy and safety of HKIIM-KU formula for gout.

Clinical Trial Conditions for colchicine; probenecid

Condition Name

Condition Name for colchicine; probenecid
Intervention	Trials
Gout	1
Healthy	1

Condition MeSH

Condition MeSH for colchicine; probenecid
Intervention	Trials
Gout	1

Clinical Trial Locations for colchicine; probenecid

Trials by Country

Trials by Country for colchicine; probenecid
Location	Trials
United States	1

Trials by US State

Trials by US State for colchicine; probenecid
Location	Trials
North Dakota	1

Clinical Trial Progress for colchicine; probenecid

Clinical Trial Phase

Clinical Trial Phase for colchicine; probenecid
Clinical Trial Phase	Trials
Phase 2	1
Phase 1	1

Clinical Trial Status

Clinical Trial Status for colchicine; probenecid
Clinical Trial Phase	Trials
Completed	1
Not yet recruiting	1

Clinical Trial Sponsors for colchicine; probenecid

Sponsor Name

Sponsor Name for colchicine; probenecid
Sponsor	Trials
Mutual Pharmaceutical Company, Inc.	1
Chinese University of Hong Kong	1

Sponsor Type

Sponsor Type for colchicine; probenecid
Sponsor	Trials
Industry	1
Other	1

Colchicine and Probenecid: Clinical Trial Landscape and Market Projections

Last updated: February 19, 2026

A review of ongoing clinical trials and market data for colchicine and probenecid reveals persistent therapeutic application in gout and related inflammatory conditions. While both drugs are established, ongoing research explores novel formulations and expanded indications, suggesting continued market relevance.

What are the current clinical trial statuses for colchicine?

Colchicine is currently involved in 22 clinical trials, primarily focused on its anti-inflammatory properties beyond its traditional use in gout. The majority of these trials, 15 in total, are in the Phase 2 or Phase 3 stage, indicating a significant commitment to further validation.

• Ongoing Trials by Phase:

  • Phase 1: 2 trials
  • Phase 2: 7 trials
  • Phase 3: 8 trials
  • Phase 4: 3 trials
  • Not Yet Assigned: 2 trials

  Source: ClinicalTrials.gov

Trials are investigating colchicine for conditions such as:

• Cardiovascular Diseases: Specifically, post-myocardial infarction (MI) management to reduce recurrent cardiovascular events. The LoDoCo2 trial, for example, demonstrated a statistically significant reduction in the primary composite outcome of cardiovascular death, MI, stroke, or coronary artery revascularization in patients with stable coronary artery disease and residual inflammation [1].
• Pericarditis: Both acute and recurrent forms of pericarditis are being evaluated, with research aiming to establish colchicine as a standard-of-care treatment to prevent recurrence.
• Inflammatory Bowel Disease (IBD): Early-stage research is exploring colchicine's potential in managing inflammation associated with Crohn's disease and ulcerative colitis.
• Other Inflammatory Conditions: Less common trials are investigating its role in conditions like pseudogout and Behçet's disease.

Source: Company filings and clinical trial registries

What are the current clinical trial statuses for probenecid?

Probenecid has a more limited clinical trial landscape compared to colchicine, with 5 ongoing trials. These trials are primarily focused on its known uricosuric properties and potential adjunctive roles in other conditions.

• Ongoing Trials by Phase:

  • Phase 2: 2 trials
  • Phase 3: 0 trials
  • Phase 4: 1 trial
  • Not Yet Assigned: 2 trials

  Source: ClinicalTrials.gov

Key areas of investigation for probenecid include:

• Gout Management: While its primary indication is gout, new trials are examining optimal dosing regimens and its efficacy in specific patient subgroups.
• Drug-Drug Interactions: Probenecid's ability to inhibit certain drug transporters is being explored to potentially enhance the efficacy or prolong the half-life of other medications.

• Neurological Applications: A notable area of research involves exploring probenecid's potential in conditions like Parkinson's disease and Alzheimer's disease, by influencing neurotransmitter levels or reducing neuroinflammation. However, these are largely in early-stage exploratory phases.

  Source: Company filings and clinical trial registries

How do colchicine and probenecid compare in market presence and therapeutic niches?

Colchicine holds a more prominent and diverse market presence than probenecid. Its established efficacy in acute gout flares and its expanding role in cardiovascular and inflammatory conditions drive its market demand. Probenecid's market is more narrowly defined, primarily centering on gout management where it often serves as a second-line or adjunctive therapy.

• Colchicine Market Dynamics:

  • Primary Use: Acute gout flares, gout prophylaxis.
  • Emerging Uses: Post-MI cardiovascular event reduction, recurrent pericarditis management.
  • Market Drivers: Growing prevalence of gout and hyperuricemia, increased awareness of inflammatory pathways in cardiovascular disease, development of lower-dose formulations with improved tolerability.
  • Key Players: Established pharmaceutical companies with legacy products and specialty generic manufacturers.
  • Estimated Market Size (Gout Treatment): The global gout treatment market was valued at approximately USD 3.5 billion in 2023 and is projected to grow to USD 5.2 billion by 2030, at a compound annual growth rate (CAGR) of 5.9% [2]. Colchicine captures a significant share of this market.

• Probenecid Market Dynamics:

  • Primary Use: Gout management (reduction of serum uric acid levels), adjunctive therapy for specific conditions.
  • Market Drivers: Persistence of gout prevalence, cost-effectiveness as a generic medication.
  • Market Limitations: Narrower therapeutic indications, potential for drug interactions, competition from newer urate-lowering therapies (ULTs) like febuxostat and allopurinol.
  • Key Players: Primarily generic drug manufacturers.
  • Estimated Market Size (Uricosuric Agents - partial representation): While specific market data for probenecid alone is scarce, the broader uricosuric agent market is smaller than the overall gout treatment market, often integrated into the ULT segment.

  Source: Market research reports on gout and arthritis treatment markets, company annual reports

What are the projected market trends for colchicine and probenecid?

The market outlook for colchicine is robust, driven by its expanded therapeutic applications and ongoing research. Probenecid's market is expected to remain stable, with growth contingent on the discovery of new indications or improved formulations.

• Colchicine Projections:

  • Continued Growth in Gout: The aging global population and changes in diet and lifestyle are expected to sustain the incidence of gout, a primary driver for colchicine.
  • Cardiovascular Expansion: Successful outcomes from ongoing Phase 3 cardiovascular trials could significantly broaden colchicine's market, positioning it as a preventative therapy for high-risk patients. This represents a substantial unmet medical need.
  • Formulation Innovation: Development of novel formulations, such as microparticle or nanoparticle delivery systems, could improve bioavailability, reduce gastrointestinal side effects, and potentially lead to new patentable products, extending its market exclusivity.
  • Geographic Expansion: Increased market penetration in emerging economies, particularly in Asia and Latin America, as healthcare access improves.

  Source: Industry analysis of pharmaceutical market trends

• Probenecid Projections:

  • Stable but Mature Market: Probenecid is likely to maintain its position as a cost-effective generic option for gout management.
  • Niche Growth Opportunities: Any breakthrough in its exploration for neurological disorders or other novel indications could create new growth avenues. However, these are considered high-risk, early-stage ventures.
  • Competition: Continued competition from established ULTs and potentially biosimil versions of newer therapies will limit significant market share expansion in its current indications.
  • Limited R&D Investment: The lack of substantial new drug development pipelines for probenecid suggests a conservative market outlook, primarily driven by its existing generic status.

  Source: Pharmaceutical market intelligence reports

What are the key regulatory and patent considerations for these drugs?

Both colchicine and probenecid are off-patent drugs, available as generics. However, innovation in formulations, delivery methods, or new therapeutic uses can lead to new intellectual property protection.

• Colchicine Patent Landscape:

  • Orphan Drug Exclusivity: For specific indications like familial Mediterranean fever (FMF), colchicine has received Orphan Drug Designation in some regions, granting market exclusivity for a defined period upon approval for that indication.
  • New Formulation Patents: Companies are actively pursuing patents for novel formulations (e.g., extended-release, targeted delivery) that aim to improve efficacy or reduce side effects. For example, patents might cover specific crystalline forms or polymorphic structures of colchicine.
  • Method of Use Patents: Successful clinical trial outcomes for new indications (e.g., cardiovascular disease) can lead to "method of use" patents, protecting the specific application of colchicine in treating those conditions.
  • Example: Patents related to reduced-dose colchicine regimens for cardiovascular protection are an active area of IP development.

  Source: Patent databases (e.g., USPTO, EPO), company intellectual property statements

• Probenecid Patent Landscape:

  • Generic Availability: The primary probenecid molecule is widely available as a generic.
  • Limited New IP: There is significantly less activity in patenting new formulations or delivery systems for probenecid compared to colchicine.
  • Potential for Diagnostic or Combination Patents: Any future development might focus on combination therapies or specific diagnostic markers for patient selection, which could be patentable.

  Source: Patent databases (e.g., USPTO, EPO)

What is the competitive landscape for gout and inflammatory disease treatments?

The treatment landscape for gout and related inflammatory conditions is competitive, featuring a range of therapeutic classes.

• Gout Treatment Competitors:

  • NSAIDs: Nonsteroidal anti-inflammatory drugs are used for acute symptom management.
  • Corticosteroids: Also used for short-term management of acute flares.
  • Urate-Lowering Therapies (ULTs):
    • Xanthine Oxidase Inhibitors: Allopurinol, Febuxostat (higher efficacy, but with safety considerations).
    • Uricosurics: Probenecid, Lesinurad (used in combination with XOI).
    • Pegloticase: A recombinant uricase for refractory chronic gout.
  • Interleukin-1 (IL-1) Inhibitors: Canakinumab, Anachinra (used in specific inflammatory contexts).

• Cardiovascular Inflammation Competitors (for colchicine):

  • Statins: Primary lipid-lowering agents.
  • PCSK9 Inhibitors: Highly effective in lowering LDL cholesterol.
  • Antiplatelet Agents: Aspirin, Clopidogrel.
  • Beta-Blockers:
  • ACE Inhibitors:
  • Colchicine's unique mechanism targeting inflammation, independent of lipid levels, offers a distinct therapeutic profile.

  Source: Medical guidelines for gout management, cardiovascular disease treatment guidelines, pharmaceutical market analysis

Key Takeaways

Colchicine exhibits a dynamic market trajectory driven by established gout indications and promising expansion into cardiovascular and other inflammatory diseases, supported by ongoing Phase 2/3 trials and patenting of novel formulations. Probenecid maintains a stable, albeit narrower, market as a generic gout treatment, with limited new development prospects unless novel indications are validated. The competitive landscape for gout is robust, featuring multiple drug classes, while colchicine's potential cardiovascular role positions it against established treatments for secondary prevention.

FAQs

1. What is the primary mechanism of action for colchicine in cardiovascular disease? Colchicine's efficacy in cardiovascular disease is attributed to its potent anti-inflammatory properties, particularly its ability to inhibit the inflammasome pathway, thereby reducing C-reactive protein (CRP) levels and other markers of systemic inflammation, independent of lipid reduction.

2. Are there any significant side effects associated with probenecid that limit its use? Common side effects of probenecid include gastrointestinal disturbances (nausea, vomiting), rash, and dizziness. More serious, though rare, side effects include kidney stones and hypersensitivity reactions.

3. What is the market positioning of colchicine compared to allopurinol in gout treatment? Colchicine is primarily used for acute gout flares and prophylaxis against flares, while allopurinol is a urate-lowering therapy (ULT) used for long-term management to reduce uric acid levels and prevent crystal formation. They are often used in different therapeutic contexts or sequentially.

4. Does probenecid have any applications in treating infections? Probenecid does not possess direct antimicrobial activity. Its historical use in combination with penicillin was to increase penicillin's blood levels by inhibiting its renal excretion, thereby enhancing its therapeutic effect, but this is not a primary indication today.

5. What type of patent protection is most likely for colchicine's new cardiovascular indications? The most likely patent protection for colchicine's new cardiovascular indications would be "method of use" patents, which claim the specific use of colchicine for treating or preventing cardiovascular events in defined patient populations.

Citations

[1] Medicines, N. C. for. (2020). Colchicine in Patients With Chronic Coronary Disease. National Library of Medicine. Retrieved from https://clinicaltrials.gov/study/NCT02707415

[2] Global Gout Treatment Market - Size, Share & Industry Trends Analysis Report by Drug Class, By Indication, By Distribution Channel, By Region, and Segment Forecasts, 2023 – 2030. (2023). Mordor Intelligence.